TG Therapeutics (TGTX) Is Up 9.7% After Six-Year BRIUMVI MS Data Shows Sustained Efficacy and Safety

• TG Therapeutics recently presented updated six-year data from the ULTIMATE I & II Phase 3 trials at the ECTRIMS annual meeting, showing that nearly 90% of relapsing multiple sclerosis patients treated with BRIUMVI remained free from disability progression and maintained a strong safety profile.
• An especially important finding was a very low relapse rate over six years and no increase in serious infection risk, further reinforcing BRIUMVI’s role in long-term multiple sclerosis care.
• We’ll explore how the sustained efficacy and safety highlighted in the new trial data could impact TG Therapeutics’ investment outlook.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

TG Therapeutics Investment Narrative Recap

To believe in TG Therapeutics as a shareholder, an investor needs to see BRIUMVI’s long-term efficacy and safety as a sustainable advantage in a competitive multiple sclerosis market. The recent six-year trial results substantially reinforce the argument that BRIUMVI can defend its place, but the company’s reliance on this single product remains the central near-term catalyst, and the biggest risk, especially as payers push for self-administered therapies; the latest data does not materially lessen this risk but may support near-term confidence in BRIUMVI’s market position.

Among recent announcements, the initiation of a Phase 3 trial for subcutaneous BRIUMVI, referenced earlier this month, directly addresses one of TG’s most important potential growth drivers and may be pivotal in counteracting competitive and payer-driven shifts toward self-administered treatments, complementing the long-term efficacy profile highlighted in the new ULTIMATE I & II data.

Yet, investors should be aware that as strong as these new efficacy signals may be, the company’s heavy dependence on BRIUMVI still means…

Read the full narrative on TG Therapeutics (it's free!)

TG Therapeutics' outlook anticipates $1.2 billion in revenue and $469 million in earnings by 2028. This scenario assumes annual revenue growth of 39.5% and an earnings increase of about $408 million from current earnings of $60.5 million.

Uncover how TG Therapeutics' forecasts yield a $40.50 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Six private investors in the Simply Wall St Community set fair value estimates for TGTX ranging from US$12.34 to US$138.37 per share. With the upcoming subcutaneous BRIUMVI a key catalyst, such differences in outlook show why it pays to compare multiple points of view.

Explore 6 other fair value estimates on TG Therapeutics - why the stock might be worth less than half the current price!

Build Your Own TG Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your TG Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com